We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Abbott Diagnostics

Download Mobile App

ThermoGenesis Develops Blood Test to Detect COVID-19 in Minutes

By LabMedica International staff writers
Posted on 06 Apr 2020
Print article
Image: SARS-CoV-2 (COVID-19) IgM/IgG Antibody Fast Detection Kit (Photo courtesy of ThermoGenesis Holdings, Inc.)
Image: SARS-CoV-2 (COVID-19) IgM/IgG Antibody Fast Detection Kit (Photo courtesy of ThermoGenesis Holdings, Inc.)
ThermoGenesis Holdings, Inc. (Rancho Cordova, CA, USA), which provides automated cell processing tools and services in the cell and gene therapy field, has developed an advanced point-of-care test that will allow rapid diagnosis of the COVID-19 virus, including asymptomatic cases, using just a single drop of blood without the need for special lab equipment and deliver results in less than 10 minutes.

ThermoGenesis develops, commercializes and markets a range of automated technologies for CAR-T and other cell-based therapies. The company currently markets a full suite of solutions for automated clinical biobanking, point-of-care applications, and automation for immuno-oncology, including its semi-automated, functionally-closed CAR-TXpress platform, which streamlines the manufacturing process for the emerging CAR-T immunotherapy market.

ThermoGenesis’ SARS-CoV-2 (COVID-19) IgM/IgG Antibody Fast Detection Kit is designed to allow pre-screening for COVID-19 infections as well as identification of individuals who have encountered the virus and have developed protective immunity. Requiring just a single drop of blood, the Kit is intended for professional use and will deliver results — with no lab equipment necessary — in less than 10 minutes, at the point-of-care. The company is currently completing validations in accordance with the “Policy for Diagnostic Test for Coronavirus Disease – 2019 during the Public Health Emergency: Immediately in Effect Guidance for Clinical Laboratories, Commercial Manufacturer, and Food and Drug Administration Staff issued on March 16, 2020 for Serological Diagnostics.” ThermoGenesis will notify the FDA upon completion of validation prior to product launch.

“The company has been in discussions with healthcare distributors, healthcare institutions, medical practitioners and government agencies, and is working quickly to bring the COVID-19 Test Kits to the US professional medical community,” said Chris Xu, Ph.D, Chief Executive Officer of ThermoGenesis. “This Kit will not only allow pre-screening for COVID-19 infections, but will also allow identification of individuals who have encountered the virus and have developed protective immunity. This will be essential in expediting the safety required to get the nation back to work in the future.”

Related Links:
ThermoGenesis Holdings, Inc.

Print article


Molecular Diagnostics

view channel
Image: Pre-eclampsia: high magnification micrograph of hypertrophic decidual vasculopathy, as seen in pregnancy-induced hypertension. (Photo courtesy of Wikimedia Commons)

Serum MicroRNAs Predict Likelihood of Pregnant Women Developing Pre-Eclampsia

MicroRNA biomarkers have been identified in the blood of asymptomatic pregnant women that can be used to predict the potential onset of pre-eclampsia. Pre-eclampsia (PE) is a disorder of pregnancy characterized... Read more


view channel
Image: Stenotrophomonas maltophilia colonies on sheep blood agar. Cultivation 48 hours in an aerobic atmosphere, 37 °C (Photo courtesy of microbiologyinpictures).

Global Spread of the Multi-Resistant Pathogen Stenotrophomonas Maltophilia Revealed

Stenotrophomonas maltophilia strains occur in several natural and human associated ecosystems. The bacterium was long regarded as relatively unproblematic, but is now considered to be one of the most feared... Read more
Copyright © 2000-2020 Globetech Media. All rights reserved.